Concept buy Aquila inks immuno-oncology deal with Macrophage Pharma

Aquila BioMedical will help Macrophage Pharma identify the best immuno-oncology candidate to enter the clinic. (Aquila)

Concept Life Sciences’ recent acquisition of Aquila BioMedical has quickly produced a return—an extended contract with Macrophage Pharma to support its preclinical immuno-oncology programs.

Aquila will run a few in vitro, in vivo and ex vivo analyses to help Macrophage decide on the best candidate to enter the clinic.

U.K.-based Macrophage targets cancer with its proprietary Esterase Sensitive Motif (ESM) technology, which delivers small-molecule drugs to influence only tumor-associated macrophages so that their suppression on the body’s natural immune system could be lifted.


Like this story? Subscribe to FierceBiotech!

Biopharma is a fast-growing world where big ideas come along every day. Our subscribers rely on FierceBiotech as their must-read source for the latest news, analysis and data in the world of biotech and pharma R&D. Sign up today to get biotech news and updates delivered to your inbox and read on the go.

Recently released results from early preclinical examinations of the biotech’s lead candidate, MPL-5821, a macrophage-targeting p38 MAP kinase inhibitor, showed that it works in a highly selective manner that spares other immune cells, and that it has potential clinical implications in lung cancer. Human testing is expected to start in 2018, and Macrophage says on its website that drugs have been synthesized targeting other enzymes such as histone deacetylase, Hsp90 and IKappaB-2.

RELATED: Concept buys preclinical CRO that specializes in immunology, immuno-oncology

Aquila Chief Operating Officer Clare Doris said the two companies’ previous collaboration “has established innovative and tailored biology solutions, producing high-value mechanistic data that will help progress its promising molecules to the clinic.”

The CRT Pioneer Fund-founded biotech recently raised £9 million in a series A round backed by CPF, Novo Nordisk’s early-stage investment sister Novo Seeds and Dutch venture capital firm Aglaia. Merck Ventures later joined with an equal size of investment.

“Macrophage Pharma impressed us with the initial data generated,” Hakan Goker, senior investment director at Merck Ventures, said in a statement at the time. “The differentiated, novel approach they are following in the TME offers promise for the immuno-oncology armory of clinicians to address a broad range of cancers.”

Aquila specializes in multiplex histology, analyzing immunomodulatory effects of treatments within the tumor microenvironment, and it was just bought by Concept Life Sciences for its expertise in the human immune system.

Suggested Articles

Oncology is clearly a major medical and societal issue, but one that sees too much focus from biopharmas at the expense of other killers.

Durect’s share price fell 12% after half of the panel of painkiller experts recommended against approving Posimir.

China-based cancer and autoimmune disease biotech I-Mab Biopharma has raised $104 million on the U.S. Nasdaq composite.